Arthur D. Little Inc.

11/20/2026 | Press release | Distributed by Public on 11/19/2026 03:02

Arthur D. Little Sets Out a Policy Agenda to Advance Patient Access to Innovative Regenerative Medicine in Japan

Arthur D. Little Japan, Inc. (ADL; headquartered in Minato-ku, Tokyo; Partner, Representative in Japan: Kensuke Sobue) has published a white paper entitled Establishing an Ecosystem That Supports Improved Patient Access to Innovative Regenerative Medicine: Public-Private Investment and Institutional Foundations Required to Build a Strategic Industry. Developed under the supervision of academic experts, the publication examines the policy measures needed to improve patient access to regenerative medicine and foster the sustained development of Japan's regenerative medicine industry.

Regenerative medicine (RM) products hold the promise of treating serious diseases that conventional therapies have struggled to address and of delivering therapeutic benefit that endures. Yet, measured per capita, Japan today treats only about 40% as many patients with these products as France and Germany, and shifts in the external environment threaten to widen the access gap further. At the same time, much of the domestic supply depends on overseas manufacturing, representing lost business opportunities for Japanese manufacturers, a continuing outflow of capital, and a growing risk to economic security.

Were policy support to be extended beyond development and manufacturing to encompass commercialization, Japan's RM ecosystem could mature to the point where, by 2035, patient access matches that of leading European countries. Including the spillover effects on supply-chain companies, such as domestic contract development and manufacturing organizations (CDMOs), the RM ecosystem and related industries could grow into a sector generating approximately JPY 1 trillion in aggregate annual sales by 2035, while strengthening Japan's economic security and contributing to regional revitalization.

These support policies would expand the use of RM products, and healthcare expenditure in 2035 would rise by approximately JPY 90 billion relative to the continued proportional use of conventional treatment. This increase would be more than offset by approximately JPY 100 billion in tax and social insurance revenues generated by the growth of the ecosystem and by patients returning to work. The net effect on health insurance and related public finances would therefore be positive.

  • Despite these strengths, Japan's RM ecosystem remains underdeveloped relative to those in Europe and the United States, and patient access remains limited.

¹ The number of newly established start-ups serves as an indicator of ecosystem formation and vitality, reflecting the depth of talent, funding, and support infrastructure available for research commercialization and entrepreneurship. The figures show the annual number of new drug discovery ventures, including those focused on regenerative medicine. Data as of June 2025; source: EIGHT ROADS, Ideas for Augmenting the Japanese Biotech Ecosystem.
² Estimates based on publicly available information from cell transplantation centers in various countries and other secondary sources.
³ Forum for Innovative Regenerative Medicine (FIRM), statement submitted to the Drug Pricing Subcommittee of the Central Social Insurance Medical Council (Chuikyo), Opinions on Price Calculation for Regenerative Medicine Products (July 2025).
Source: Compiled by Arthur D. Little from secondary sources.

Advancing Patient Access and Industry Growth Through Coordinated Policy Support

  • The white paper quantitatively assesses how policy support across basic research, clinical development, manufacturing, regulatory approval, and commercialization could advance two complementary objectives: improving patient access and fostering growth in RM and related industries.
  • The analysis indicates that coordinated support across the entire value chain could help address drug lag and drug loss, expand treatment access, and substantially increase the number of products in development. By implementing all policies, patient access in Japan could reach levels comparable to those of major European countries by 2035.

Source: Arthur D. Little analysis

  • Furthermore, the combined annual revenue of companies within the RM ecosystem is projected to grow from the current estimated JPY 110 billion to approximately JPY 940 billion by 2035, indicating that the RM and related industries are expected to become a nearly JPY 1 trillion industry.

Source: Arthur D. Little analysis

Healthcare Affordability and the Broader Fiscal Impact

  • Although RM products generally entail higher drug costs per administration than conventional therapies, this does not necessarily translate into higher overall healthcare expenditure. Differences in treatment frequency and duration are central to a meaningful comparison of their respective costs.
  • The fiscal assessment also considers revenues generated by the RM ecosystem. These include corporate income tax, individual income tax, resident tax, consumption tax, and social insurance contributions from companies and employees, together with revenues attributable to patients returning to work following treatment. When these revenues are treated as offsets to the additional healthcare expenditure, the analysis indicates a positive net balance for health insurance and related public finances.
  • By implementing all policies, approximately 13,000 patients each year-including children and young adults with serious diseases-could receive innovative treatments offering the prospect of long-term remission or functional recovery. The potential to deliver these benefits without increasing the net fiscal burden relative to conventional treatment provides a strong social rationale for policies that support RM.

¹ Estimates are based on RM products already marketed in Japan, covering multiple indications and modalities. Future healthcare costs are calculated over the relevant treatment duration.

² Tax and social insurance revenues generated within the ecosystem are calculated based on annual revenues in 2035. Revenues attributable to patients returning to work are calculated over the assumed five-year duration of sustained therapeutic benefit for patients treated in 2035.

Source: Arthur D. Little analysis

Policy Recommendations

  • Establishing a well-functioning RM ecosystem would serve objectives extending beyond public health. By fostering domestic industrial development and generating wider economic benefits, such an ecosystem could contribute to regional revitalization and strengthen Japan's economic security.
  • Realizing these benefits requires coordinated support across the entire value chain. Within this broader approach, ADL's analysis identifies commercialization policies as particularly influential in expanding patient access and fostering industry growth. The white paper therefore recommends placing commercialization support at the center of Japan's efforts to build an RM ecosystem and strengthening the policies that underpin it.

GVA: Gross Value Added

Source: Prepared by Arthur D. Little

White Paper Summary

Full Text of the White Paper

The copyright of this white paper is held by Arthur D. Little Japan, Inc.

Reproduction and reuse of this white paper are permitted, provided that the source is properly acknowledged.

Introduction to the ADL Authors

Ryo Hanamura (Partner, Arthur D. Little Japan)

Hiroaki Koda (Principal, Arthur D. Little Japan)

Mai Takagi (Consultant, Arthur D. Little Japan)

Introduction to the Academic Supervisors

Shunya Ikeda (Professor, Graduate School of Medicine, International University of Health and Welfare)

Kazumasa Oguro (Professor, Faculty of Economics, Hosei University)

Hiroshi Nakamura (Professor, Graduate School of Business Administration, Keio University)

Kanetaka M. Maki (Associate Professor, Waseda Business School)

* This white paper was prepared with the sponsorship of Bristol-Myers Squibb K.K. The authors are employees of Arthur D. Little, and the academic supervisors are independent researchers affiliated with Japanese universities. Bristol-Myers Squibb K.K. was not involved in the analysis or in formulating the conclusions of this white paper. The authors retain responsibility for the analysis, conclusions, and recommendations presented herein.

Arthur D. Little Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 09:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]